Business
Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update
PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plasma NfL, a disease progression biomarker, compared to natural history Dose 2, 50% lower than Dose 1, substantially increased CSF PGRN levels at 30-days, reaching the upper limit of a healthy adult reference range Plan to amend upliFT-D protocol to include a prophylactic course of low dose anticoagulation and modify inclusion criteria to study patients earlier in disease progression Remain on track
About this update from Passage Bio, Inc.
[{"type":"image","alt":"Passage Bio","displaySize":"","headline":null,"caption":"Passage Bio","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":86,"url":"https://media.zenfs.com/en/globenewswire.com/b3c0c02f5e492ae038a6a6abc1f66d66"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/voTmQbQLiNqTa.rw6jMsmQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b3c0c02f5e492ae038a6a6abc1f66d66","width":300,"height":86}},"lazy":false},{"type":"text","content":"PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plasma NfL, a disease progression biomarker, compared to natural history","length":168,"tagName":"p"},{"type":"text","content":"Dose 2, 50% lower than Dose 1, substantially increased CSF PGRN levels at 30-days, reaching the upper limit of a healthy adult reference range","length":142,"tagName":"p"},{"type":"text","content":"Plan to amend upliFT-D protocol to include a prophylactic course of low dose anticoagulation and modify inclusion criteria to study patients earlier in disease progression","length":171,"tagName":"p"},{"type":"text","content":"Remain on track to seek regulatory feedback on FTD-GRN pivotal trial design in 1H 2026","length":86,"tagName":"p"},{"type":"text","content":"PHILADELPHIA, June 23, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported updated data from the ongoing Phase 1/2 upliFT-D clinical trial evaluating PBFT02 for the treatment of frontotemporal dementia (FTD) with granulin (GRN) mutations and provided program updates and anticipated milestones.","length":440,"tagName":"p"},{"type":"text","content":"“We are pleased to share updated data highlighting the promise of PBFT02 for the frontotemporal dementia community. These data continue to demonstrate the ability of our investigational, one-time gene therapy to elevate progranulin, the deficient protein in FTD-GRN, in a robust and durable manner while also reducing the rate of increase of plasma neurofilament levels compared to rates observed in natural history studies,” said Will Chou, M.D., president and chief executive officer of Passage Bio. “In addition, we continue to refine our understanding of the safety pr...